摘要

<正>Parkinson’s disease(PD) is the second most common neurodegenerative disease, affecting around 1.0% of the population over 65 years of age [1]. In China, there are estimated to be more than 3 million PD patients, with each year about 100,000 PD patients being newly diagnosed. Along with China stepping into an aging society, it was estimated that in 2030, there would be around 5 million PD patients in China alone, which would create huge socioeconomic burdens on patients and their families.